A Double Blind Placebo Controlled Study of Cannabis Smoking in Inflammatory Bowel Disease

Inclusion Criteria:

1. Patients with a diagnosis IBD at least 3 months before recruitment will be eligible
to the study.

2. Patients with active disease who are resistant to either 5 ASA, steroids or
immunomodulators, or who can not receive those drugs due to adverse reactions will
be offered the possibility of smoking cannabis at a dose of two cigarettes a day
which will contain either regular cannabis or pre treated cannabis as placebo.

3. Disease activity index of either CDAI of more then 200 in Crohn's disease or Mayo
score above 3 in UC.

4. Age above 20.

Exclusion Criteria:

1. Patients with a known mental disorder

2. Patients who are deemed to be at a high risk of abuse or addiction to the study drug.

3. Pregnant women

4. Patients who are sensitive to any of the ingredients of the study medication.

5. Patients who are unable to give informed consent.

6. Patients who may need surgery in the near future.